20/20 Biolabs, Inc. - Common Stock (AIDX)

Last Price1.6400

Change+0.00 (0.00%)

NASDAQ · Last Trade: Mar 25th, 4:06 AM EDT

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

Inflammatory Biomarker Tracking Predicted to Enhance

By 20/20 Biolabs Inc. · Via GlobeNewswire · March 24, 2026

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers

By 20/20 Biolabs Inc. · Via GlobeNewswire · March 12, 2026

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights

By 20/20 Biolabs Inc. · Via GlobeNewswire · February 25, 2026

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

By 20/20 Biolabs Inc. · Via GlobeNewswire · February 20, 2026